Keros Therapeutics Q4 2024 net loss $46.0M; receives $200M Takeda upfront for elritercept

Keros Therapeutics, Inc.

2024-FY EPS reported -$5.00

Net loss of $46.0M in Q4 2024 vs $40.2M in Q4 2023; full-year net loss $187.4M.
Revenue of $3.0M in Q4 2024 vs $0.1M in prior period, largely from Hansoh milestone.
Cash and equivalents $559.9M at Dec 31, 2024; plus $200M Takeda upfront payment received Feb 2025 extends runway into 2029.
Phase 1 data for KER-065 expected in Q1 2025; Phase 2 TROPOS trial data for cibotercept (KER-012) planned.
R&D expenses rose to $45.6M in Q4 2024, driven by elritercept Phase 3 and TROPOS trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.